Third Harmonic Bio is a clinical-stage company developing a first-in-class, ultra-selective oral KIT inhibitor for the treatment of severe allergy and inflammation. The company’s lead candidate, THB001, is in clinical development for chronic urticaria and has the potential to treat a broad range of mast-cell mediated dermal, respiratory and gastrointestinal allergic and inflammatory diseases. Third Harmonic went public in September 2022 (NASDAQ: THRD).
| Headquarters | Cambridge, MA |
| Website | www.thirdharmonicbio.com |
| Pipeline | Phase 1 |
| @3rdHarmonicBio | |
| Third Harmonic Bio |